Study Compares Effectiveness of TNF Blockers in Rheumatoid Arthritis Patients

A new study comparing the dose escalation patterns of rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab found that etanercept users were significantly less likely to have a dose escalation. The study, published by the American Journal of Pharmacy Benefits, notes that dose escalation is associated with higher drug treatment costs and greater risk of adverse events.

To read this American Journal of Pharmacy Benefits study in its entirety, follow this link.